Bridge Biotherapeutics Collaborates with UK’s Brainomics to Accelerate Idiopathic Pulmonary Fibrosis Clinical Trials

Objective and Quantitative Drug Effect Measurement Using Artificial Intelligence Solutions

[Asia Economy Reporter Lee Gwan-joo] Bridge Biotherapeutics announced on the 6th that it has signed a collaboration agreement with Brainomix, a UK-based AI-driven medtech company.

Bridge Biotherapeutics will utilize Brainomix's AI-based program, 'e-ILD Technology,' in the Phase 2 clinical trial of 'BBT-877,' targeting patients with idiopathic pulmonary fibrosis. By additionally using automated processed radiological data such as high-resolution computed tomography (HRCT) images of idiopathic pulmonary fibrosis patients, the company plans to enhance objectivity and efficiency in evaluating drug efficacy.

Furthermore, through this collaboration, the two companies will explore whether imaging biomarker data based on radiological imaging can be used as a new indicator for drug efficacy evaluation, alongside the widely used clinical marker in idiopathic pulmonary fibrosis clinical trials, forced vital capacity (FVC).

Recently highlighted imaging biomarkers quantify results such as patient diagnosis, staging, disease prognosis prediction, and treatment responsiveness evaluation through radiological data, aiding quantitative analysis. As an indicator that helps medical professionals diagnose patients more intuitively, it is increasingly utilized in clinical trials for various diseases, promoting overall clinical research cost and time efficiency, as well as playing a crucial role in accelerating regulatory approvals.

Jung Su-jin, Head of Clinical Development, stated, "Based on Brainomix's unique AI-based imaging technology and expertise, we expect to efficiently secure supplementary data related to the efficacy of BBT-877, enabling more successful evidence gathering not only for Phase 2 but also for subsequent clinical trials."

BBT-877 recently received approval from the U.S. Food and Drug Administration (FDA) to enter Phase 2 clinical trials and is preparing to commence multinational clinical studies.

This content was produced with the assistance of AI translation services.